All In MedTech

Device Trial Radar · NCT02351726

Mitroflow DL Post Approval Study- North America

Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment Post Approval Study

Last checked: Nov 20, 2026Latest source record: Feb 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

186

Actual

Start

Mar 2015

Primary completion

Dec 31, 2019

Study completion Dec 31, 2019

Sponsor

Lead sponsor
LivaNovaPublic (LIVN)
Sponsor type
Industry
First posted
Jan 30, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, non-randomized, multicenter post-approval study to collect long term clinical and echographic data on Mitroflow DL patients.

Conditions

  • Aortic Stenosis
  • Aortic Regurgitation
  • Aortic Valve Insufficiency
  • Heart Valve Diseases
  • Cardiovascular Abnormalities
  • Cardiovascular Diseases
  • Congenital Abnormalities
  • Heart Diseases
  • Pathological Conditions, Anatomical

Interventions

  • Mitroflow DLDevice

    Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of structural Valve Deterioration in Implanted PatientsTime frame: 8 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • Sharp Memorial Hospital

    San Diego, California

  • River City Clinical Research

    Jacksonville, Florida

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.